Free Trial

Sage Therapeutics (SAGE) Competitors

Sage Therapeutics logo
$8.80 +0.04 (+0.46%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$8.80 +0.00 (+0.06%)
As of 07/25/2025 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SAGE vs. AGIO, TWST, INDV, RXRX, DNLI, BEAM, KNSA, BLTE, CNTA, and VCEL

Should you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), Indivior (INDV), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry.

Sage Therapeutics vs. Its Competitors

Sage Therapeutics (NASDAQ:SAGE) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Sage Therapeutics currently has a consensus price target of $8.02, suggesting a potential downside of 8.92%. Agios Pharmaceuticals has a consensus price target of $57.33, suggesting a potential upside of 43.33%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Sage Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sage Therapeutics
1 Sell rating(s)
14 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.93
Agios Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

Agios Pharmaceuticals has lower revenue, but higher earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$41.24M13.36-$400.67M-$5.80-1.52
Agios Pharmaceuticals$36.50M63.47$673.72M$11.243.56

Agios Pharmaceuticals has a net margin of 1,798.26% compared to Sage Therapeutics' net margin of -747.63%. Agios Pharmaceuticals' return on equity of -2.75% beat Sage Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sage Therapeutics-747.63% -68.99% -60.67%
Agios Pharmaceuticals 1,798.26%-2.75%-2.52%

99.2% of Sage Therapeutics shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by insiders. Comparatively, 4.3% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sage Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Sage Therapeutics. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 4 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of 1.00 beat Agios Pharmaceuticals' score of 0.57 indicating that Sage Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sage Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Agios Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Agios Pharmaceuticals beats Sage Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Sage Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SAGE vs. The Competition

MetricSage TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$548.56M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-1.5221.1828.1020.05
Price / Sales13.36286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book1.168.378.665.87
Net Income-$400.67M-$55.19M$3.25B$258.55M
7 Day Performance-3.40%5.88%4.22%3.73%
1 Month Performance-5.17%17.33%10.51%11.75%
1 Year Performance-19.93%4.42%34.40%18.03%

Sage Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SAGE
Sage Therapeutics
3.4092 of 5 stars
$8.80
+0.5%
$8.02
-8.9%
-16.0%$548.56M$41.24M-1.52690News Coverage
Upcoming Earnings
AGIO
Agios Pharmaceuticals
4.3602 of 5 stars
$39.23
+0.5%
$58.60
+49.4%
-17.5%$2.27B$37.04M3.49390Upcoming Earnings
Analyst Forecast
TWST
Twist Bioscience
4.3776 of 5 stars
$37.80
-0.6%
$50.40
+33.3%
-37.4%$2.26B$312.97M-11.63990News Coverage
Positive News
INDV
Indivior
1.1456 of 5 stars
$15.62
+1.0%
$17.00
+8.8%
+30.9%$2.15B$1.17B-50.391,051News Coverage
Analyst Forecast
RXRX
Recursion Pharmaceuticals
0.7942 of 5 stars
$5.28
flat
$7.00
+32.6%
-19.4%$2.15B$59.82M-2.98400
DNLI
Denali Therapeutics
4.2644 of 5 stars
$14.69
+1.2%
$33.71
+129.5%
-43.3%$2.13B$330.53M-5.50430News Coverage
Positive News
Upcoming Earnings
BEAM
Beam Therapeutics
2.2287 of 5 stars
$21.17
+0.0%
$48.75
+130.3%
-32.5%$2.13B$63.52M-4.59510Analyst Revision
KNSA
Kiniksa Pharmaceuticals International
3.4615 of 5 stars
$28.80
+2.5%
$39.33
+36.6%
+1.6%$2.10B$423.24M-115.20220News Coverage
BLTE
Belite Bio
1.7877 of 5 stars
$63.58
+0.6%
$96.67
+52.0%
+28.7%$2.02BN/A-46.7510High Trading Volume
CNTA
Centessa Pharmaceuticals
3.3291 of 5 stars
$15.13
+4.9%
$27.89
+84.3%
+49.8%$2.02B$15M-8.36200Insider Trade
High Trading Volume
VCEL
Vericel
3.6821 of 5 stars
$39.82
-0.3%
$61.14
+53.5%
-22.4%$2.00B$238.54M1,327.78300News Coverage
Positive News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:SAGE) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners